Imugene’s off-the-shelf CAR T therapy azer-cel has won FDA Fast Track Designation for relapsed or refractory CLL/SLL and MZL, backed by compelling Phase 1b response rates.
- FDA grants Fast Track for azer-cel in CLL/SLL and MZL
- 100% overall response rate in CAR T-naive CLL/SLL patients
- 83% response rate including four complete responses in MZL
- Fast Track enables accelerated regulatory engagement and review
- Azer-cel offers rapid off-the-shelf CAR T-cell therapy alternative
FDA Fast Track Boosts Imugene’s Clinical Momentum
Imugene Limited (ASX:IMU) has taken a significant regulatory step with the US Food and Drug Administration granting Fast Track Designation to its lead allogeneic CAR T-cell therapy, azer-cel, for two challenging blood cancers: relapsed or refractory Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL) and Marginal Zone Lymphoma (MZL). This designation is designed to expedite development and facilitate more frequent FDA interactions for therapies addressing serious conditions with unmet needs.
The Fast Track status means Imugene could benefit from rolling review processes and potential eligibility for Accelerated Approval and Priority Review, streamlining the pathway toward market access if clinical milestones are met.
Promising Phase 1b Data Underpin Regulatory Nod
Azer-cel’s clinical promise is underscored by Phase 1b basket trial results showing a 100% overall response rate (ORR) in CAR T-naive patients with CLL/SLL, a patient group that had undergone a median of three or more prior therapies. This is a notable achievement given the refractory nature of these cancers and the limited options available.
Meanwhile, in MZL, a typically indolent but incurable B-cell lymphoma, the therapy demonstrated an 83% ORR, including four complete responses among six evaluable patients who had received multiple prior lines of treatment. These figures highlight azer-cel’s potential to deliver meaningful clinical benefit across multiple B-cell malignancies.
Off-the-Shelf CAR T Therapy Addresses Key Limitations
Azer-cel distinguishes itself from traditional autologous CAR T therapies by being an off-the-shelf, CD19-targeted treatment derived from pre-manufactured donor T-cells. This approach overcomes the typical three to six weeks manufacturing delay, enabling administration within days, an advantage for patients with aggressive or refractory disease.
Imugene’s CEO Leslie Chong emphasised the significance of the Fast Track Designation, stating it reflects the "meaningful clinical activity" observed and will enhance regulatory dialogue as the program advances. This regulatory momentum complements the company’s ongoing efforts to expand azer-cel’s clinical trial scope, including recent moves to combine it with BTK inhibitors for resistant lymphoma patients, broadening its therapeutic reach.
Bottom Line?
Azer-cel’s Fast Track status signals regulatory confidence but the path to approval hinges on confirming these early response rates in larger trials.
Questions in the middle?
- Will azer-cel maintain its high response rates in larger, later-stage studies?
- How will Imugene position azer-cel against emerging off-the-shelf CAR T competitors?
- What timeline can investors expect for key regulatory milestones and potential approval?